Alimohammadi R, Mahmoodi Chalbatani G, Alimohammadi M, Ghaffari-Nazari H, Rahimi A, Mortaz E, Mossafa N, Boon L, Jalali SA (2023) Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. Sci Rep 13:2472

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basudan AM (2022) The role of immune checkpoint inhibitors in cancer therapy. Clin Pract 13:22–40

Article  PubMed  PubMed Central  Google Scholar 

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B (2017) TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun 8:2256

Article  PubMed  PubMed Central  Google Scholar 

Bougras-Cartron G, Nadaradjane A, Joalland MP, Lalier-Bretaudeau L, Raimbourg J, Cartron PF (2023) Adenosine methylation level of miR-125a-5p promotes anti-PD-1 therapy escape through the regulation of IGSF11/VSIG3 expression. Cancers (Basel) 15:3188

Article  CAS  PubMed  Google Scholar 

Davis LE, Shalin SC, Tackett AJ (2019) Current state of melanoma diagnosis and treatment. Cancer Biol Ther 20:1366–1379

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, Andersen MH, Thor Straten P, Svane IM (2015) Aberrant expression of MHC Class II in melanoma attracts inflammatory tumor-specific CD4+ T- cells, which dampen CD8+ T cell antitumor reactivity. Can Res 75:3747–3759

Article  CAS  Google Scholar 

ElTanbouly MA, Schaafsma E, Noelle RJ, Lines JL (2020) VISTA: coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol 200:120–130

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eom DS, Inoue S, Patterson LB, Gordon TN, Slingwine R, Kondo S, Watanabe M, Parichy DM (2012) Melanophore migration and survival during zebrafish adult pigment stripe development require the immunoglobulin superfamily adhesion molecule Igsf11. PLoS Genet 8:e1002899

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (2019) Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Ann Meet 39:147–164

Article  Google Scholar 

Ghorbaninezhad F, Masoumi J, Bakhshivand M, Baghbanzadeh A, Mokhtarzadeh A, Kazemi T, Aghebati-Maleki L, Shotorbani SS, Jafarlou M, Brunetti O, Santarpia M, Baradaran B, Silvestris N (2022) CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro. Front Immunol 13:931316

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghouzlani A, Rafii S, Karkouri M, Lakhdar A, Badou A (2020) The promising IgSF11 immune checkpoint is highly expressed in advanced human gliomas and associates to poor prognosis. Front Oncol 10:608609

Article  PubMed  Google Scholar 

Harada H, Suzu S, Hayashi Y, Okada S (2005) BT-IgSF, a novel immunoglobulin superfamily protein, functions as a cell adhesion molecule. J Cell Physiol 204:919–926

Article  CAS  PubMed  Google Scholar 

Huang X, Zhang X, Li E, Zhang G, Wang X, Tang T, Bai X, Liang T (2020) VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol 13:83

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jang S, Oh D, Lee Y, Hosy E, Shin H, van Riesen C, Whitcomb D, Warburton JM, Jo J, Kim D, Kim SG, Um SM, Kwon SK, Kim MH, Roh JD, Woo J, Jun H, Lee D, Mah W, Kim H, Kaang BK, Cho K, Rhee JS, Choquet D, Kim E (2016) Synaptic adhesion molecule IgSF11 regulates synaptic transmission and plasticity. Nat Neurosci 19:84–93

Article  CAS  PubMed  Google Scholar 

Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (Baltimore, Md: 1950) 177:896–904

Article  CAS  Google Scholar 

Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RY, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang YK, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ (2019) VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574:565–570

Article  CAS  PubMed  Google Scholar 

Kim H, Takegahara N, Choi Y (2023) IgSF11-mediated phosphorylation of pyruvate kinase M2 regulates osteoclast differentiation and prevents pathological bone loss. Bone Res 11:17

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS (2018) VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol Immunother: CII 67:1113–1121

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W, Liu Z, Jin K, Shao F, Zeng H, Wang Y, Zhu Y, Xu L, Wang Z, Chang Y, Zhang W (2023) Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. BMC Cancer 23:661

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lotfinejad P, Kazemi T, Safaei S, Amini M, Roshani Asl E, Baghbani E, Sandoghchian Shotorbani S, Jadidi Niaragh F, Derakhshani A, Abdoli Shadbad M, Silvestris N, Baradaran B (2021) PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T cell-induced pro-inflammatory cytokines. Biomed Pharmacother = Biomed Pharmacotherapie 138:111436

Article  CAS  Google Scholar 

Mahdavi Gorabi A, Sadat Ravari M, Sanaei M-J, Davaran S, Kesharwani P, Sahebkar A (2022) Immune checkpoint blockade in melanoma: advantages, shortcomings and emerging roles of the nanoparticles. Int Immunopharmacol 113:109300

Article  CAS  PubMed  Google Scholar 

Marei HE, Hasan A, Pozzoli G, Cenciarelli C (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23:64

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin AS, Molloy M, Ugolkov A, von Roemeling RW, Noelle RJ, Lewis LD, Johnson M, Radvanyi L, Martell RE (2023) VISTA expression and patient selection for immune-based anticancer therapy. Front Immunol 14:1086102

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marzagalli M, Ebelt ND, Manuel ER (2019) Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol 59:236–250

Article  CAS  PubMed  Google Scholar 

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B (2019) Corrigendum: the TNF paradox in cancer progression and immunotherapy. Front Immunol 10:2515

Article  PubMed  PubMed Central  Google Scholar 

Okubo Y, Mera T, Wang L, Faustman DL (2013) Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2. Sci Rep 3:3153

Article  PubMed  PubMed Central  Google Scholar 

Olbromski M, Mrozowska M, Piotrowska A, Smolarz B, Romanowicz H (2024) The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma. Cancer Immunol Immunother: CII 73:136

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patwekar M, Sehar N, Patwekar F, Medikeri A, Ali S, Aldossri RM, Rehman MU (2024) Novel immune checkpoint targets: a promising therapy for cancer treatments. Int Immunopharmacol 126:111186

Article  CAS  PubMed  Google Scholar